A UC Riverside team built a battery-powered gel that pumps oxygen deep into chronic wounds. In diabetic mice, untreated injuries were often fatal, but treated wounds healed in 23 days. The implications go way beyond band-aids.
Imagine a wound that simply refuses to close. Your body tries to heal it, but the tissue underneath is slowly suffocating. No oxygen can reach the deepest layers, so instead of rebuilding, the wound just… rots. For millions of diabetic patients worldwide, this isn't a hypothetical. It's a Tuesday.
Now imagine a gel that breathes for you, pumping oxygen directly into that dying tissue like a tiny life-support machine. A team at UC Riverside just published results showing this gel did something almost unheard of in preclinical research: untreated diabetic mice saw their wounds fail to close, and the injuries were often fatal. The mice that got the gel? Wounds healed in about 23 days. They survived.
The study landed in Nature Communications Materials in February 2026, and the implications stretch far beyond wound care.
A Wound That Eats You Alive
To understand why this matters, you need to understand what diabetic foot ulcers actually do to people.
Diabetes damages blood vessels and nerves over time, especially in the feet. Roughly 15–25% of diabetic patients will develop a foot ulcer during their lifetime. When those ulcers refuse to heal, and many don't, the consequences are brutal. Globally, 50–70% of all non-traumatic lower-limb amputations are caused by diabetes. That's not a typo. More than half.
Every 3.5 minutes, someone on this planet loses a limb because of a diabetic foot complication. In the U.S. alone, there were about 185,000 lower-limb amputations in 2022, and diabetes was behind the vast majority. If you survive the amputation, the five-year survival rate is just 43%. That's worse than many cancers.
The core problem is deceptively simple: the wound can't get enough oxygen. Deep tissue layers become hypoxic, starved of the oxygen needed to grow new blood vessels, fight infection, and rebuild. Think of it like trying to keep a campfire going in a sealed room. Eventually the flame dies, no matter how much wood you throw on it. Current treatments try to address this, but most only deliver oxygen to the surface. The deep tissue stays suffocated.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A Battery-Powered Oxygen Factory the Size of a Band-Aid
The UC Riverside team, led by Associate Professor of Bioengineering Iman Noshadi, built something elegantly simple. Their gel is made of water and a choline-based liquid, choline being a nutrient your body already knows and tolerates. The gel is soft, flexible, and molds itself into every crevice and contour of a wound before solidifying in place.
The magic happens when you attach a tiny battery, roughly the size of the ones in hearing aids. That battery triggers an electrochemical reaction that splits the water molecules inside the gel. The byproduct? A steady, continuous stream of oxygen, delivered directly into the deepest tissue layers.
It's essentially a miniature oxygen factory that you wear on your wound.
Unlike existing oxygen therapies that provide short bursts to the wound surface, this gel can keep pumping oxygen for up to a month. That timeline matters enormously because growing new blood vessels (a process called vascularization) takes weeks. You can't kickstart healing with a few hours of oxygen. The tissue needs sustained delivery, and that's exactly what this gel provides.
But oxygen delivery is only half the story. The choline in the gel pulls double duty. It's naturally antibacterial, which helps fend off infection. And it tamps down the excessive inflammation that plagues chronic wounds by neutralizing reactive oxygen species, destructive molecules that accumulate in damaged tissue and essentially keep the wound in a constant state of biological panic.
Think of it as both the firefighter and the fire truck. It puts out the inflammation while simultaneously delivering the oxygen the tissue needs to rebuild.
The Mouse Study That Turned Heads
The team tested the gel on diabetic and aged mice, models specifically chosen because their wounds closely mimic the chronic, non-healing wounds seen in older adults and diabetic patients.
The results were stark. Untreated mice saw their wounds fail to close, and the injuries were often fatal. The wound just wouldn't heal, and the animals deteriorated. When the oxygen gel was applied and replaced weekly, wounds closed in approximately 23 days, and the treated animals survived.
In preclinical research, you rarely see such a clean separation between treated and untreated groups. Most mouse studies show incremental improvements: a wound closes 20% faster, an infection clears a bit sooner. This wasn't incremental. The gap between outcomes was a chasm.
PhD student Prince David Okoro, a co-author on the study, noted the gel's practical design: "We could make this patch as a product where the gel may need to be renewed periodically." The weekly replacement schedule tested in mice suggests a product that patients or caregivers could realistically manage at home.
A $10 Billion Problem Begging for Better Answers
The diabetic foot ulcer treatment market is projected to hit roughly $10–11 billion in 2026 and could grow to over $15 billion by the early 2030s. That growth is being driven by a depressing reality: diabetes rates keep climbing, and current treatments still leave millions of patients without good options.
The competitive landscape today is a patchwork. Advanced wound dressings hold the biggest market share at about 43%. Negative pressure wound therapy (essentially vacuum devices that suck fluid from wounds) is the fastest-growing segment. Biologics and skin substitutes, like products from Organogenesis, have shown closure rates as high as 70–86% in certain ulcer grades.
But topical oxygen therapy, which is what the UC Riverside gel falls under, has been gaining traction as a category. Existing oxygen therapies have shown they can heal certain types of diabetic ulcers, particularly less severe ones. The limitation has always been depth of delivery: getting oxygen past the wound surface and into the tissue that actually needs it.
That's precisely the problem Noshadi's gel was designed to solve. If it works in humans the way it worked in mice, it wouldn't just compete with existing oxygen therapies. It could leapfrog them entirely.
The Sleeper Application Nobody's Talking About
Wound healing is the obvious use case. But the researchers have their eye on something potentially bigger: lab-grown organs and tissues.
One of the greatest unsolved problems in regenerative medicine is oxygen delivery. When scientists try to grow thick tissue in a lab (think a chunk of liver or a section of heart muscle) the cells on the outside get plenty of oxygen, but the cells deep inside starve. Passive diffusion, the body's natural method of distributing oxygen, only works across very thin layers. It's why most lab-grown tissues today are paper-thin.
If you could actively pump oxygen into thick tissue constructs, you'd solve one of the fundamental bottlenecks in the entire field. Noshadi's gel could become the essential plumbing that tissue engineers have been missing: a way to keep deep cells alive and functional while the tissue grows.
That's the kind of platform technology that starts as a wound-care product and quietly becomes infrastructure for an entire industry.
What Comes Next (And Why You Shouldn't Hold Your Breath)
The team has been clear that further research and clinical trials are needed before this gel reaches patients. No timeline for human trials has been publicly announced, and the technology is still in the preclinical stage.
Translating preclinical results to humans is famously treacherous. Mice are not people, and plenty of therapies that looked miraculous in rodents have flopped in clinical trials. The history of wound care is littered with promising preclinical candidates that couldn't replicate their results in human skin.
That said, a few things work in this gel's favor. The materials (water and choline) are biocompatible and already well-understood. The battery technology is proven and tiny. The manufacturing concept seems straightforward. And the unmet medical need is enormous, which could help with regulatory pathways and reimbursement.
Other oxygen-delivering therapies in development, like the topical bioreactor AUP-16 currently in Phase II trials, are estimated to be at least four years from market maturity. The UC Riverside gel would need to navigate a similar timeline: preclinical optimization, safety studies, then Phase I, II, and III clinical trials. We're likely looking at several years minimum before this could reach patients.
Why This One Feels Different
Biotech is full of spectacular mouse data that never amounts to anything in humans. So why pay attention to this one?
Because the mechanism is elegant and the problem is massive. Chronic wounds affect an estimated 12 million Americans annually, and roughly one in five of those patients ends up losing a limb. Current solutions are expensive, often inadequate, and mostly treat the surface while ignoring the suffocating tissue underneath.
This gel attacks the root cause, hypoxia, with a delivery method that's sustained, deep-reaching, and built from materials the body already tolerates. It's not a drug that needs to hit a specific molecular target. It's oxygen. The most fundamental requirement for cellular life, delivered where it's needed most.
The gap between untreated and treated mice in this study wasn't subtle. It was the difference between wounds that wouldn't close and wounds that healed completely. Between death and survival.
Now comes the hard part: proving it works in us.
Global Pharma & Supply Chain4 min read
India's $30 Billion Generic Drug Machine Is Just Getting Warmed Up
India's pharma exports just blew past $30 billion, and the industry is gunning for double-digit growth next year. For Western biopharma, that means more pricing pressure on generics, and a whole new tier of manufacturing partners knocking on the door.
